Aperio Group LLC raised its position in shares of Icon Plc (NASDAQ:ICLR) by 5.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,958 shares of the medical research company’s stock after buying an additional 822 shares during the period. Aperio Group LLC’s holdings in Icon Plc were worth $1,703,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. IHT Wealth Management LLC increased its holdings in shares of Icon Plc by 16.9% during the second quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock worth $223,000 after buying an additional 24 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in shares of Icon Plc during the second quarter worth approximately $103,000. Acrospire Investment Management LLC increased its holdings in shares of Icon Plc by 20.1% during the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after buying an additional 200 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of Icon Plc by 20.7% during the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock worth $133,000 after buying an additional 217 shares in the last quarter. Finally, Huntington National Bank increased its holdings in shares of Icon Plc by 5.0% during the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after buying an additional 77 shares in the last quarter. 91.59% of the stock is owned by institutional investors.
Several analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Icon Plc from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Jefferies Group LLC reissued a “buy” rating on shares of Icon Plc in a research note on Sunday, July 30th. ValuEngine cut shares of Icon Plc from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. KeyCorp reissued an “overweight” rating and set a $125.00 price target (up from $115.00) on shares of Icon Plc in a research note on Monday. They noted that the move was a valuation call. Finally, SunTrust Banks, Inc. raised shares of Icon Plc from a “hold” rating to a “buy” rating and increased their price target for the company from $93.00 to $126.00 in a research note on Monday, July 31st. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $121.00.
COPYRIGHT VIOLATION NOTICE: “Icon Plc (ICLR) Stake Increased by Aperio Group LLC” was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/16/icon-plc-iclr-stake-increased-by-aperio-group-llc.html.
Icon Plc (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. Icon Plc had a net margin of 16.37% and a return on equity of 28.42%. The firm had revenue of $440.30 million for the quarter, compared to analysts’ expectations of $438.09 million. During the same period last year, the firm earned $1.19 earnings per share. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. equities research analysts predict that Icon Plc will post 5.36 EPS for the current year.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.